Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis.
暂无分享,去创建一个
[1] J. Galambos,et al. Natural history of alcoholic hepatitis. II. The long-term prognosis. , 1971, The American journal of gastroenterology.
[2] H. Nomura,et al. Prevalence of fatty liver in a general population of Okinawa, Japan. , 1988, Japanese journal of medicine.
[3] F. Schaffner,et al. Effect of weight reduction on hepatic abnormalities in overweight patients. , 1990, Gastroenterology.
[4] R. Hanson,et al. The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.
[5] C. Gluud,et al. Hepatic effects of dietary weight loss in morbidly obese subjects. , 1991, Journal of hepatology.
[6] C. Tiribelli,et al. Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study , 1994, Hepatology.
[7] M. Bennett,et al. The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.
[8] G. Gores,et al. Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.
[9] L Dalla Palma,et al. Noninvasive in vivo quantitative assessment of fat content in human liver. , 1997, Journal of hepatology.
[10] K. Tanikawa,et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.
[11] D. Sautereau,et al. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. , 1998, Journal of hepatology.
[12] F. Schick,et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.
[13] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[14] S. Caldwell,et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.
[15] M. Başaranoǧlu,et al. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. , 1999, Journal of hepatology.
[16] K. Batts,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.
[17] P. Thuluvath,et al. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.
[18] P. Giral,et al. Liver fibrosis in overweight patients. , 2000, Gastroenterology.
[19] J. Lavine. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.
[20] M. Graif,et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. , 2000, Investigative radiology.
[21] Marco Zoli,et al. Metformin in non-alcoholic steatohepatitis , 2001, The Lancet.
[22] M. Gambardella,et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.
[23] K. Lindor,et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study , 2001 .
[24] P. D. James,et al. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. , 2001, Journal of hepatology.
[25] E. Brunt. Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.
[26] F Vinicor,et al. The continuing epidemics of obesity and diabetes in the United States. , 2001, JAMA.
[27] F. Brancati,et al. Nonalcoholic fatty liver disease: The most common cause of abnormal liver enzymes in the U.S. population , 2001 .
[28] K. Lindor,et al. Treatment of Nonalcoholic Fatty Liver: Present and Emerging Therapies , 2001, Seminars in liver disease.
[29] P. Giral,et al. Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.
[30] D. Kotler,et al. Liver Pathology in Morbidly Obese Patients Undergoing Roux-en-Y Gastric Bypass Surgery , 2002, Obesity surgery.
[31] K. Flegal,et al. Prevalence and trends in obesity among US adults, 1999-2000. , 2002, JAMA.
[32] G. Loss,et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.
[33] F. Brancati,et al. The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.
[34] C. Degott,et al. Fasting in obesity , 1982, Digestive Diseases and Sciences.